查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1318984

新抗原標靶治療市場：按適應症疾病、新抗原類型、免疫治療類型、給藥途徑- 全球預測 2023-2030

Neoantigen Targeted Therapies Market by Target Disease Indication, Neoantigens Type, Immunotherapy Type, Route of Administration - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年全球新抗原標靶治療市場將達33,128.2億美元，年複合成長率為38.50%，大幅成長，2030年將達32,418.9百萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球新抗原標靶治療市場至關重要。透過檢視業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使用戶能夠根據自己的具體需求做出資訊的決策。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.新抗原標靶治療藥物的全球市場規模及預測如何？

2.在預測期內，COVID-19對全球新抗原標靶治療市場的阻礙因素與影響為何？

3.在預測期內，全球新抗原標靶治療市場需要投資哪些產品/細分市場/應用/領域？

4.新抗原標靶治療的全球市場競爭策略為何？

5. 全球新抗原標靶治療市場的技術趨勢和法律規範是什麼？

6.全球新抗原標靶治療市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入新抗原標靶治療的全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 新抗原標靶治療日益普及
      • 癌症患者數量快速增加
      • 世界各地的老年人口正在增加
      • 醫療基礎建設發展
    • 抑制因素
      • 與新抗原標靶治療相關的副作用
    • 機會
      • 癌症治療的技術進步
      • 增加政府投資，包括贖回計劃
    • 任務
      • 新抗原鑑定的挑戰
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 新抗原標靶治療藥物市場（依目標疾病區分）

  • 骨癌
  • 大腸直腸癌
  • 婦科癌症
  • 非小細胞肺癌
  • 腎臟細胞癌

第7章 新抗原標靶治療藥物市場（以新抗原類型）

  • 現成的新抗原
  • 個人化新抗原

第8章 以免疫標靶治療市場

  • 樹突細胞疫苗
  • 基於 DNA/RNA 的疫苗
  • 蛋白質/胜肽疫苗
  • 基於 TIL 的治療方法

第9章 新抗原標靶治療市場：依給藥途徑

  • 皮內
  • 靜脈
  • 皮下的

第10章 美洲新抗原標靶治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太新抗原標靶治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲新抗原標靶治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第14章上市公司名單

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-43078BB92C81

The Global Neoantigen Targeted Therapies Market is forecasted to grow significantly, with a projected USD 3,312.82 million in 2023 at a CAGR of 38.50% and expected to reach a staggering USD 32,418.90 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Neoantigen Targeted Therapies Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Neoantigen Targeted Therapies Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Target Disease Indication, market is studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma. The Colorectal Cancer is projected to witness significant market share during forecast period.

Based on Neoantigens Type, market is studied across Off-the-Shelf Neoantigens and Personalized Neoantigens. The Off-the-Shelf Neoantigens is projected to witness significant market share during forecast period.

Based on Immunotherapy Type, market is studied across Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, and TIL-Based Therapies. The TIL-Based Therapies is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Intradermal, Intravenous, and Subcutaneous. The Intravenous is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Neoantigen Targeted Therapies Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neoantigen Targeted Therapies Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neoantigen Targeted Therapies Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neoantigen Targeted Therapies Market?

4. What is the competitive strategic window for opportunities in the Global Neoantigen Targeted Therapies Market?

5. What are the technology trends and regulatory frameworks in the Global Neoantigen Targeted Therapies Market?

6. What is the market share of the leading vendors in the Global Neoantigen Targeted Therapies Market?

7. What modes and strategic moves are considered suitable for entering the Global Neoantigen Targeted Therapies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Neoantigen Targeted Therapies Market, by Target Disease Indication, 2022 vs 2030
  • 4.3. Neoantigen Targeted Therapies Market, by Neoantigens Type, 2022 vs 2030
  • 4.4. Neoantigen Targeted Therapies Market, by Immunotherapy Type, 2022 vs 2030
  • 4.5. Neoantigen Targeted Therapies Market, by Route of Administration, 2022 vs 2030
  • 4.6. Neoantigen Targeted Therapies Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the popularity of neoantigen targeted therapies
      • 5.1.1.2. Surge in number of cancer patients
      • 5.1.1.3. Increase in the geriatric population across the globe
      • 5.1.1.4. Developing healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with neoantigen targeted therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the cancer treatment
      • 5.1.3.2. Increasing government investment such as reimbursement plan
    • 5.1.4. Challenges
      • 5.1.4.1. Challenges of neoantigen identification
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Neoantigen Targeted Therapies Market, by Target Disease Indication

  • 6.1. Introduction
  • 6.2. Bone Cancer
  • 6.3. Colorectal Cancer
  • 6.4. Gynecological Cancer
  • 6.5. Non-Small Cell Lung Cancer
  • 6.6. Renal Cell Carcinoma

7. Neoantigen Targeted Therapies Market, by Neoantigens Type

  • 7.1. Introduction
  • 7.2. Off-the-Shelf Neoantigens
  • 7.3. Personalized Neoantigens

8. Neoantigen Targeted Therapies Market, by Immunotherapy Type

  • 8.1. Introduction
  • 8.2. Dendritic Cell Vaccines
  • 8.3. DNA / RNA-Based Vaccines
  • 8.4. Protein / Peptide-based Vaccines
  • 8.5. TIL-Based Therapies

9. Neoantigen Targeted Therapies Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intradermal
  • 9.3. Intravenous
  • 9.4. Subcutaneous

10. Americas Neoantigen Targeted Therapies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Neoantigen Targeted Therapies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Neoantigen Targeted Therapies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2022 VS 2030
  • FIGURE 3. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2022 VS 2030 (%)
  • FIGURE 5. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2022 VS 2030 (%)
  • FIGURE 6. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2022 VS 2030 (%)
  • FIGURE 7. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 8. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. NEOANTIGEN TARGETED THERAPIES MARKET DYNAMICS
  • FIGURE 10. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 5. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 191. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 192. NEOANTIGEN TARGETED THERAPIES MARKET LICENSE & PRICING